Braveheart Bio files for IPO, plans two global Phase 3 trials for HCM drug BHB-1893

Braveheart Bio, Inc. filed an S-1 registration statement with the SEC on July 14, 2026 for an initial public offering, seeking to list on Nasdaq under the ticker "BRVE." The company has applied to list its common stock on The Nasdaq Global Market under the symbol "BRVE."¹

The company's lead and only product candidate is BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM and non-obstructive HCM.¹ The drug was originally discovered and developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. in China, and all clinical trials completed to date were designed, sponsored, and conducted by Hengrui, primarily in China, with one Phase 1 trial in Australia.¹ Braveheart obtained worldwide rights excluding Greater China to BHB-1893 in September 2025 through an exclusive license agreement.¹

On the clinical timeline, the company expects to initiate LIONHEART-HCM, its global Phase 3 trial in oHCM, in the second half of 2026, and NOBLEHEART-HCM, its global Phase 3 trial in nHCM, in the first half of 2027.¹

In prior trials run by Hengrui, patients in Cohort 2 of the Phase 2 oHCM study experienced an 86% complete response rate at Week 12.¹ In the nHCM Phase 2 study, BHB-1893-treated patients showed rapid, substantial, and statistically significant reductions in secondary cardiac biomarker endpoints.¹

On financing, Braveheart has raised approximately $185 million since inception from a group of life sciences investors.¹ Financial statements show net losses of $14.3 million for the three months ended March 31, 2026 and $66.1 million for the year ended December 31, 2025, with an accumulated deficit of $80.3 million as of March 31, 2026.¹